## Highlights of This Issue

### EDITORIAL

**Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies**
David Olmos, Bristi Basu, and Johann S. de Bono

**Significance of Cancer Stem Cell-Defining Molecules**
Stephen B. Keysar and Antonio Jimeno

**Triethylenetetramine Pharmacology and Its Clinical Applications**
Jun Lu

### REVIEWS

**Dihydroartemisinin Induces Apoptosis by a Bak-Dependent Intrinsic Pathway**
René Handrick, Teona Ontikatze, Kerstin-Daniela Bauer, Florian Freier, Amelie Rüebel, Jan Dürrig, Claus Belka, and Verena Jendrossek

**From NPC Therapeutic Target Identification to Potential Treatment Strategy**

**Architectonics of Phage-Liposome Nanowebs as Optimized Photosensitizer Vehicles for Photodynamic Cancer Therapy**
Sreeram Kalarical Janardhanan, Shoba Narayanan, Gopal Abbineni, Andrew Hayhurst, and Chuanbin Mao

**Substitution of Adenovirus Serotype 3 Hexon onto a Serotype 5 Oncolytic Adenovirus Reduces Factor X Binding, Decreases Liver Tropism, and Improves Antitumor Efficacy**
Joshua J. Short, Angel A. Rivera, Hongju Wu, Mark R. Walter, Masato Yamamoto, J. Michael Mathis, and David T. Curiel

**The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias**
Kensuke Kojima, Jared K. Burks, Janine Arts, and Michael Andreeff

**BNP7787-Mediated Modulation of Paclitaxel- and Cisplatin-Induced Aberrant Microtubule Protein Polymerization In vitro**
Aulma R. Parker, Pavankumar N. Petluru, Meizhen Wu, Min Zhao, Harry Kochat, and Frederick H. Hausheer

### THERAPEUTIC DISCOVERY

**Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors**

**PIM Kinase Inhibitors Downregulate STAT3 Tyr705 Phosphorylation**
Marisa Chang, Nisha Kanwar, Eric Feng, Allan Siu, Xiujie Liu, Duwei Ma, and Jan Jongstra

**Activating Stress-Activated Protein Kinase–Mediated Cell Death and Inhibiting Epidermal Growth Factor Receptor Signaling: A Promising Therapeutic Strategy for Prostate Cancer**
Raj Kumar, Sowmyalakshmi Srinivasan, Pallab Pahari, Jürgen Rohr, and Chendil Damodaran

### PRECLINICAL DEVELOPMENT

**The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias**
Kensuke Kojima, Jared K. Burks, Janine Arts, and Michael Andreeff

**BNP7787-Mediated Modulation of Paclitaxel- and Cisplatin-Induced Aberrant Microtubule Protein Polymerization In vitro**
Aulma R. Parker, Pavankumar N. Petluru, Meizhen Wu, Min Zhao, Harry Kochat, and Frederick H. Hausheer
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2568</td>
<td>Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells</td>
<td>Ruman Rahman, Teresa Osteso-Ibanez, Robert A. Hirst, Jane Levesley, John-Paul Kilday, Siobhan Quinn, Andrew Peet, Chris O’Callaghan, Beth Coyle, and Richard G. Grundy</td>
</tr>
<tr>
<td>2582</td>
<td>A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model</td>
<td>N.V. Rajeshkumar, Zeshaan A. Rasheed, Elena García-García, Fernando López-Ríos, Kosaku Fujiwara, William H. Matsui, and Manuel Hidalgo</td>
</tr>
<tr>
<td>2605</td>
<td>Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells</td>
<td>Chandramu Chetty, Sajani S. Lakka, Praveen Bhoopathi, Christopher S. Gondi, Krishna Kumar Veeravalli, Daniel Fassett, Jeffrey D. Klopfenstein, Dzung H. Dinh, Meena Gujrati, and Jasti S. Rao</td>
</tr>
<tr>
<td>2627</td>
<td>Molecular Therapy Targeting Sonic Hedgehog and Hepatocyte Growth Factor Signaling in a Mouse Model of Medulloblastoma</td>
<td>Valerie Coon, Tamara Laukert, Carolyn A. Pedone, John Laterra, K. Jin Kim, and Daniel W. Fults</td>
</tr>
</tbody>
</table>

### CORRECTION

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2637</td>
<td>Correction: ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells</td>
<td></td>
</tr>
</tbody>
</table>

### ABOUT THE COVER

A new nanoweb-like drug delivery system integrating cationic liposomes that encapsulated photosensitizer and filamentous M13 phages that were genetically engineered to display anionic peptides on side walls was developed. Morphological evolution of the phage-liposome complexes was studied, and their chemical and biological properties were evaluated for possible application in drug delivery. The study highlights the ability of the phage-liposome nanowebs to serve as efficient carriers to transport photosensitizer to cancer cells. For details, see article by Kalarical Janardhanan and colleagues on page 2524.
Molecular Cancer Therapeutics

9 (9)

Mol Cancer Ther 2010;9:2447-2637.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/9/9

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.